Long-Read Genome Sequencing Diagnoses Rare Condition
By LabMedica International staff writers Posted on 06 Jul 2017 |
Carney complex arises from mutations in the Protein Kinase CAMP-Dependent Type I Regulatory Subunit Alpha (PRKAR1A) gene, and is characterized by increased risk for several tumor types, particularly in the heart and hormone-producing glands, such as ovaries, testes, adrenal glands, pituitary gland and thyroid.
Current clinical genomics assays primarily utilize short-read sequencing (SRS), but SRS has limited ability to evaluate repetitive regions and structural variants. Long-read sequencing (LRS) has complementary strengths, and LRS could offer a means to identify overlooked genetic variation in patients undiagnosed by SRS.
Scientists at Stanford University Medical Center (Stanford, CA, USA) and their colleagues performed low-coverage genome LRS to identify structural variants in a patient who presented with multiple neoplasia and cardiac myxomata, in whom the results of targeted clinical testing and genome SRS were negative. Genome sequencing involves snipping DNA into pieces, reading the fragments, and then using a computer to patch the sequence together. DNA carries our genetic blueprint in a double-stranded string of molecular "letters" called nucleotides, or base pairs. The study was carried out in collaboration with Pacific Biosciences, a biotechnology company (Menlo Park, CA, USA).
The team found that the LRS approach yielded 6,971 deletions and 6,821 insertions greater than 50 bp. Filtering for variants that are absent in an unrelated control and overlap a disease gene coding exon identified three deletions and three insertions. One of these, a heterozygous 2,184 bp deletion, overlaps the first coding exon of PRKAR1A, which is implicated in autosomal dominant Carney complex. RNA sequencing demonstrated decreased PRKAR1A expression. The deletion was classified as pathogenic based on guidelines for interpretation of sequence variants.
Euan Ashley, DPhil, FRCP, professor of cardiovascular medicine, of genetics and of biomedical data science, and senior author of the study, said, “This allows us to illuminate dark corners of the genome like never before. Technology is such a powerful force in medicine. It's mind-blowing that we are able to routinely sequence patients' genomes when just a few years ago this was unthinkable.” The study was published on June 22, 2017, in the journal GENETICS in MEDICINE.
Related Links:
Stanford University Medical Center
Pacific Biosciences
Current clinical genomics assays primarily utilize short-read sequencing (SRS), but SRS has limited ability to evaluate repetitive regions and structural variants. Long-read sequencing (LRS) has complementary strengths, and LRS could offer a means to identify overlooked genetic variation in patients undiagnosed by SRS.
Scientists at Stanford University Medical Center (Stanford, CA, USA) and their colleagues performed low-coverage genome LRS to identify structural variants in a patient who presented with multiple neoplasia and cardiac myxomata, in whom the results of targeted clinical testing and genome SRS were negative. Genome sequencing involves snipping DNA into pieces, reading the fragments, and then using a computer to patch the sequence together. DNA carries our genetic blueprint in a double-stranded string of molecular "letters" called nucleotides, or base pairs. The study was carried out in collaboration with Pacific Biosciences, a biotechnology company (Menlo Park, CA, USA).
The team found that the LRS approach yielded 6,971 deletions and 6,821 insertions greater than 50 bp. Filtering for variants that are absent in an unrelated control and overlap a disease gene coding exon identified three deletions and three insertions. One of these, a heterozygous 2,184 bp deletion, overlaps the first coding exon of PRKAR1A, which is implicated in autosomal dominant Carney complex. RNA sequencing demonstrated decreased PRKAR1A expression. The deletion was classified as pathogenic based on guidelines for interpretation of sequence variants.
Euan Ashley, DPhil, FRCP, professor of cardiovascular medicine, of genetics and of biomedical data science, and senior author of the study, said, “This allows us to illuminate dark corners of the genome like never before. Technology is such a powerful force in medicine. It's mind-blowing that we are able to routinely sequence patients' genomes when just a few years ago this was unthinkable.” The study was published on June 22, 2017, in the journal GENETICS in MEDICINE.
Related Links:
Stanford University Medical Center
Pacific Biosciences
Latest Molecular Diagnostics News
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans
- Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset
- Blood Test Could Detect HPV-Associated Cancers 10 Years before Clinical Diagnosis
- Low-Cost Point-Of-Care Diagnostic to Expand Access to STI Testing